BioSkryb Genomics, Research Instruments Offering Single-cell Technologies To Singapore, Southeast Asia

KUALA LUMPUR, Aug 30 (Bernama) -- BioSkryb Genomics has announced a partnership with Research Instruments Pte Ltd, to distribute BioSkryb’s ResolveDNA and ResolveOME single cell amplification tools throughout Singapore and Southeast Asia.

Research Instruments (Everlife-RI) is part of Everlife Asia, an Asia-focused market access and distribution group with strong capabilities in life sciences, clinical diagnostics, and analytical instrumentation operating in seven countries across Asia.

“We look forward to working with Everlife-RI to bring the power of ResolveOME and ResolveDNA to more researchers and investigators in Southeast Asia and enable greater insights into how complex diseases function.

“Expanding into these critical markets will support scientific breakthroughs in research, diagnostics and treatments through increased access to the unmatched resolution of our single cell multiomics platforms,” said BioSkryb Genomics Chief Executive Officer (CEO), Suresh Pisharody in a statement.

Meanwhile, Everlife-Research Instruments CEO, Yeo Seok Hoon said: “BioSkryb’s single cell amplification tools offer an unprecedented multiomic view at single-cell resolution, and we look forward to working with them to increase access to these powerful solutions throughout Southeast Asia.”

BioSkryb’s ResolveDNA genome amplification technology enables researchers to accurately examine whole genomes, whole exomes, and low-input DNA samples from single cells to reveal novel insights on the molecular drivers of disease.

ResolveOME is a first of its kind multiomic solution that combines whole genome or exome analysis with whole transcriptome analysis within each individual cell in an integrated workflow and can help investigators explore complex multiomic datasets at scale.

Powered by BioSkryb’s patented primary template-directed amplification (PTA) technology, ResolveOME and ResolveDNA dramatically increase genomic coverage to 97 per cent.

Headquartered in Durham, North Carolina, the United States, BioSkryb Genomics is a rapidly growing organisation that is transforming single cell molecular discovery and analysis.

-- BERNAMA

Sompo International Appoints Vicky Sarjeant As Head Of Energy Insurance, APAC

KUALA LUMPUR, Aug 30 (Bernama) -- Sompo International Holdings Ltd, a global provider of commercial and consumer property and casualty (re)insurance, has appointed Vicky Sarjeant as Head of Energy Insurance, Asia Pacific (APAC).

In a statement, Sompo International said she will be based in Singapore and report to President of Commercial Lines, Insurance, APAC, Paul O’Neill.

“With 17 years of knowledge and experience in both the London and Singapore markets, Vicky will be a valuable addition to our growing team in the APAC region.

“I look forward to working with her as we continue establishing our practice and growing our book of business,” O’Neill said.

Before joining Sompo International, Sarjeant was an Energy Underwriter at Canopius Asia, covering the APAC and Middle East and North Africa regions. Previously, she held positions with Marsh Singapore and Miller Insurance in London.

A Bermuda-based holding company, Sompo International is an indirect wholly owned subsidiary of Sompo Holdings Inc, with more than 9,000 employees.

-- BERNAMA

Roaming Fraud Losses Reach US$8 Bln By 2028 - Juniper Research

 

KUALA LUMPUR, Aug 29 (Bernama) -- A new study from Juniper Research has found losses from global roaming fraud are anticipated to exceed US$8 billion by 2028, driven by the increase in bilateral roaming agreements for data-intensive use cases over 5G networks. (US$1=RM4.65)

In turn, it predicts fraudulent data traffic will account for 80 per cent of global operator roaming-based losses by 2024, according to Juniper Research in a statement.

As 2G and 3G networks are sunsetting, operators are accelerating the transition to 5G and VoLTE roaming services to leverage the high levels of virtualisation and lower operational costs.

However, the highly virtualised nature of 5G networks is creating more opportunities for fraudsters to deploy their attacks; leaving operator networks open to emerging fraud tactics over 5G networks.

As bilateral 5G roaming agreements proliferate, the research predicts operators will deploy more sophisticated fraud mitigation tools.

The greater amount of data that 5G roaming connections generate will require the development of solutions that can detect fraudulent users and traffic over new 5G networks as they evolve.

An example is the rise in 5G subscription fraud, whereby fraudsters create new subscriptions with false information; incurring roaming charges without intending to pay. Until the subscription is cancelled, fraudsters will continue anonymously using 5G roaming data, with operators losing potential roaming revenue.

Fraud mitigation services will alert operators of any potentially fraudulent activity across 5G networks in real‑time and enable them to identify and block suspicious roaming subscribers, enabling operators to minimise fraudulent activity; reducing the impact on their roaming revenue.

-- BERNAMA

Catcha Investment Notified On Late Form 10-Q Filing

KUALA LUMPUR, Aug 29 (Bernama) -- Catcha Investment Corp (Catcha) announced that New York Stock Exchange Regulation Inc, has notified the company that it was not in compliance with NYSE American’s continued listing standards because it did not timely file its Quarterly Report on Form 10-Q for the quarter June 30, which was due on Aug 21.

In accordance with Section 1007 of the NYSE American Company Guide, the company will have six months from the date of the notice (Initial Cure Period), to file the Form 10-Q with the Securities and Exchange Commission (SEC).

If Catcha fails to file the Form 10-Q during the Initial Cure Period, NYSE American LLC (Exchange) may, in its sole discretion, provide an additional six-month cure period (Additional Cure Period).

The company can regain compliance with the Exchange’s continued listing standards at any time during the Initial Cure Period or Additional Cure Period, as applicable, by filing the Form 10-Q and any subsequent delayed filings with the SEC.

On Aug 14, Catcha filed a notification of late filing on Form 12b-25, indicating that the filing of its Form 10-Q will be delayed.

Although the company has dedicated significant resources to the completion of finalising its consolidated financial statements and related disclosures for inclusion in the Form 10-Q, it was unable to file the form prior to the prescribed due date, the extension period provided by the Form 12b-25.

In a statement, Catcha said additional time is needed to complete its review of the financial statements included in the Form 10-Q in order to ensure a complete, accurate form.

The company intends to file the Form 10-Q as soon as practicable and in any event within the above-referenced six-month period.

Catcha is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganisation, or similar business combination with one or more businesses.

-- BERNAMA

TOSHIBA PRODUCES INDUSTRY'S FIRST 2200V DUAL SILICON CARBIDE MOSFET MODULE

 

KUALA LUMPUR, Aug 29 (Bernama) -- Toshiba Electronic Devices & Storage Corporation (Toshiba) has developed “MG250YD2YMS3”, the industry’s first 2200 volt (V) dual silicon carbide (SiC) MOSFET module for industrial equipment.

The new module has a drain current (DC) rating of 250A and uses the company’s third generation SiC MOSFET chips.

According to Toshiba in a statement, it is suitable for applications that use DC1500V, such as photovoltaic power systems and energy storage systems.

Industrial applications like those mentioned above generally use DC1000V or lower power, and their power devices are mostly 1200V or 1700V products.

However, anticipating widespread use of DC1500V in coming years, Toshiba has released the industry’s first 2200V product.

Toshiba will continue to meet the market needs for high efficiency and the downsizing of industrial equipment.

-- BERNAMA

AI-Media Unveils Groundbreaking AI-Powered LEXI Captioning Tool Kit

KUALA LUMPUR, Aug 25 (Bernama) -- AI-Media, a provider of captioning technology and infrastructure, has unveiled its groundbreaking AI-Powered LEXI Captioning Tool Kit.

According to AI-Media in a statement, this comprehensive collection of automated captioning solutions marks a new era in the industry, combining cutting-edge artificial intelligence (AI) technologies to meet the integrated needs of content creators and distributors worldwide.

“Our LEXI Tool Kit is a result of years of research and development, and we are proud to offer a transformative solution that enhances the accessibility and inclusivity of media content," said AI-Media Chief Sales Officer, James Ward.

The AI-Powered LEXI Tool Kit addresses challenges faced by media companies, broadcasters, event producers, educational institutions, as well as other content producers in delivering cost-effective and accurate captions, and subtitles for live and pre-recorded content that can be easily re-used in other customer applications.

The Tool Kit comprises six key solutions each designed to address different captioning needs, enabling the consumer to mix and match key components to suit their business requirements.

The solutions are compatible with its encoder series via the iCap Cloud Network creating the ultimate captioning ecosystem, which consist of LEXI Live Automatic Captioning; LEXI Recorded; LEXI Translate; LEXI DR (Disaster Recovery); LEXI Local and LEXI Library.

Presenting a comprehensive solution to maximise the benefits of captioning and translation, the Tool Kit simplifies customer workflows by providing seamless interoperability as it is fully compatible with AI-Media's best-in-class SDI and IP caption encoders.

Founded in Australia in 2003, technology company AI-Media helps the world’s leading broadcasters, enterprises, and government agencies ensure high accuracy, secure and cost-effective captioning via its AI-powered LEXI captioning solution.

-- BERNAMA

SOMPO INTERNATIONAL NAMES ALASDAIR WALKER REGIONAL HEAD OF DISTRIBUTION, INSURANCE, APAC

KUALA LUMPUR, Aug 24 (Bernama) -- Sompo International, a global provider of commercial and consumer property and casualty (re)insurance, has appointed Alasdair Walker as Regional Head of Distribution, Insurance, Asia Pacific (APAC).

In a statement, Sompo International said he will be based in Singapore and report to President of Commercial Lines, Insurance, APAC, Paul O’Neill.

O’Neill said Walker’s appointment represented a continuation of Sompo International’s expansion through high-calibre hires in the APAC region.

“His wide range of experience across distribution channels and product lines, coupled with his commitment to deliver superior client service, leaves him singularly well-positioned to further develop our network in APAC.

“I look forward to welcoming Alasdair to our growing Singapore insurance team as we accelerate our growth in this exciting market full of opportunity,” said O’Neill.

Walker joined Sompo International from Allianz, where he held positions in London, the United Kingdom; Johannesburg, South Africa; and most recently Singapore as Regional Head of Distribution, managing a team across seven locations.

A Bermuda-based holding company, Sompo International Holdings Ltd is an indirect wholly owned subsidiary of Sompo Holdings Inc, with more than 9,000 employees.

-- BERNAMA

DUCK CREEK TIES PARTNERSHIP WITH RISK CONTROL TECHNOLOGIES

KUALA LUMPUR, Aug 22 (Bernama) -- Duck Creek Technologies has announced its partnership with Risk Control Technologies (RCT), a frontrunner in risk data management software for underwriting and loss control teams.

In a statement, Duck Creek said it will be a silver sponsor of RCT’s Loss Control Summit conference for loss control professionals from Aug 21-23, to kick off their partnership in Toronto, Canada.

“RCT’s data-driven risk management solution is paramount, especially for insurers engaged in underwriting property, casualty and workers comp lines of business.

“We look forward to continuing to cultivate our partnership and engaging with RCT’s customers at the upcoming Loss Control Summit in Toronto,” said Duck Creek Technologies Senior Partner Manager, Robert Fletcher.

Meanwhile, RCT Chief Executive Officer, David Da Costa said: “We are excited to work with Duck Creek, one of the most transformative leaders in the insurance solutions market today.

“In addition to efficiencies gained by integrating, combining loss control data with data already in Duck Creek, such as claim data, creates significant value from being able to better predict claims or optimise pricing within your book,” he added.

At the heart of Duck Creek's core solutions is Duck Creek Policy, a cutting-edge platform that offers low-code tools via a Software as a Service (SaaS) model, in which it facilitates the entire lifecycle of insurance operations and seamlessly integrates with esteemed industry collaborators.

RCT enables carriers to optimise and significantly increase their risk data coverage across their entire book of business. In addition to mitigating more claims, it positively impacts their renewal rates while also creating efficiencies for underwriters within Duck Creek.

All of this helps carriers improve their loss ratios, strengthen their customer engagements, and drive impactful operational efficiencies.

-- BERNAMA

CATCHING A GLIMPSE: WHALE WATCHING IN JANGSAENGPO, SOUTH KOREA

Attractions in Jangsaengpo Whale Culture Special Zone in Namgu Ulsan (Photo: Namgu Ulsan Metropolitan City)

KUALA LUMPUR, Aug 22 (Bernama) -- The Tourism Division of Namgu Ulsan Metropolitan City recently hosted a second press tour with foreign journalists in Korea, following the first one in May, to promote the appealing Jangsaengpo to foreign media outlets.

A beach town in Ulsan's Nam-gu district, Jangsaengpo is a popular tourist destination which was designated as a Whale Culture Zone in 2008. Also launched was a ‘Jangsaengpo whale watching cruise’, making it the only city in Korea where whales can be observed.

According to Namgu Ulsan Metropolitan City in a statement, August is the ideal month to go whale watching because of the abundance of plankton at sea.

The Whale Culture Zone combines history and culture through a variety of whale-themed attractions and programmes, including the Whale Culture Village, Whale Museum, Whale Ecology Experience Center, and monorail.

Throughout the four seasons, the Whale Culture Village hosts theme-specific festivals such as the Whale Festival, Hydrangea Festival and Horror Festival.

Meanwhile, located within the Whale Culture Village, Jangsaengpo Old Town is popular with foreign tourists, as they have the chance to play the ‘Rose of Sharon Blooms’, a popular game that appeared on Squid Game, Netflix’s popular series, and make the Korean sugar candy ‘Dalgona’.

-- BERNAMA

 

ARM ANNOUNCES PUBLIC FILING OF REGISTRATION STATEMENT FOR PROPOSED INITIAL PUBLIC OFFERING

CAMBRIDGE, England, Aug 22 (Bernama-BUSINESS WIRE) -- Arm Holdings Limited (“Arm”) today announced that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of American depositary shares (“ADS”) representing its ordinary shares. Arm has applied to list the ADSs on the Nasdaq Global Select Market under the symbol “ARM”. The number of ADSs to be offered and the price range for the proposed offering have yet to be determined.

Raine Securities LLC is acting as financial advisor in connection with the proposed offering. Barclays, Goldman Sachs & Co. LLC, J.P. Morgan, and Mizuho are acting as joint book-running managers for the proposed offering.

The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to this offering, when available, may be obtained by visiting EDGAR on the SEC's website at www.sec.gov. Alternatively, copies of the preliminary prospectus, when available, may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-888-603-5847 or by email at barclaysprospectus@broadridge.com; Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 866-471-2526 or by email at prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 866-803-9204 or by email at prospectus-eq_fi@jpmorganchase.com or Mizuho Securities USA LLC, Attention: U.S. ECM Desk, 1271 Avenue of the Americas, New York, NY 10020, by telephone at (212) 205-7602 or by email at US-ECM@mizuhogroup.com.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. The offering is subject to market and other conditions and the completion of the SEC’s review process.

About Arm

Arm is building the future of computing. Our energy-efficient processor designs and software platforms have enabled advanced computing in more than 250 billion chips and our technologies securely power products from the sensor to the smartphone and the supercomputer. Together with 1,000+ technology partners, we are enabling artificial intelligence to work everywhere, and in cybersecurity, we are delivering the foundation for trust in the digital world – from chip to cloud. The future is being built on Arm.

All information is provided "as is" and without warranty or representation. This document may be shared freely, attributed and unmodified. Arm is a registered trademark of Arm Limited (or its subsidiaries). All brands or product names are the property of their respective holders. © 1995-2023 Arm Group.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20230820117356/en/

Contact

Media
FGS Global
ArmLimited@FGSGlobal.com

Arm External Communications
Global-PRteam@arm.com

Investors
Arm Investor Relations
Ian Thornton
ian.thornton@arm.com

Source : Arm

Cellebrite Supercharges Corporate Investigative Capabilities with New SaaS Offering

TYSONS CORNER, Va. and PETAH TIKVA, Israel and ORLANDO, Fla., Aug 22 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced at ILTACON 2023 a new SaaS offering for corporate investigations and eDiscovery —Endpoint Mobile Now. This new offering will be the first Cellebrite SaaS solution for private sector customers, with Endpoint Inspector expected to be available as a SaaS option later this year.

Endpoint Mobile Now is designed to empower corporations, law firms and service providers to scale remote data collection across iOS and Android devices by leveraging Cellebrite’s SaaS infrastructure. Designed specifically for the private sector, Endpoint Inspector provides an all-in-one solution that allows examiners to legally access data, with custodians being aware that information is being collected from their devices and given their consent to remotely collect data from mobile devices, computers and cloud.

"With this new online and on-demand technology, organizations can rapidly and securely collect and preserve data for litigation or internal investigations before it is compromised or deleted," said Ken Basore, General Manager for Cellebrite Enterprise Solutions. "Endpoint Mobile Now leverages Cellebrite’s patent-pending remote collection platform in a SaaS environment and is purpose-built to meet the growing need from attorneys to access, collect and preserve mobile data necessary for civil litigation and internal investigations."

Endpoint Mobile Now provides e-discovery capabilities and a comprehensive forensic platform, enabling accurate, quick and secure data collection, management and review. Aligning specifically to organizations’ evolving budgetary requirements, Endpoint Mobile Now allows organizations to pay for collections as needed, thereby freeing up precious financial capital and IT resources.

Cellebrite’s SaaS infrastructure ensures the platform is able to adapt quickly in the constantly changing environment of mobile device applications and operating system updates and patches and evolves in real-time, regardless of device type, operating system or application. The solution also enables simultaneous remote collection of multiple mobile devices, allowing for rapid data preservation and discovery of relevant evidence, without exorbitant resource spend.

For more information on Cellebrite Endpoint Intelligence, please visit here.

About Cellebrite

Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.

About Cellebrite Enterprise Solutions

In a world that’s evolving rapidly, Cellebrite Enterprise Solutions looks beyond the horizon to design solutions to keep data within reach, transform it, and reveal important insights to protect your business and employees. From headquarters to home office, eDiscovery professionals and corporate investigators can access endpoints anywhere with Cellebrite’s enterprise solution offerings.

Caution Regarding Forward-Looking Statements

This presentation includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to estimated financial information for fiscal year 2023 such as revenue, ARR, adjusted EBITDA and earnings as well as statements related to the performance, strategies, prospects, and other aspects of Cellebrite’s business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; failure to manage its growth effectively; Cellebrite’s ability to introduce new solutions and add-ons; its dependency on its customers renewing their subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite’s solutions; near term declines in new or renewed agreements; risks associated with inability to retain qualified personnel and senior management; the security of Cellebrite’s operations and the integrity of its software solutions; risks associated with the negative publicity related to Cellebrite’s business and use of its products; risks related to Cellebrite’s intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20-F filed with the SEC on April 27, 2023 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission, which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Media

Victor Cooper
Sr. Director of Corporate Communications + Content Operations
Victor.cooper@cellebrite.com
+1 404.804.5910

Investor Relations

Andrew Kramer
Vice President, Investor Relations
investors@cellebrite.com
+1 973.206.7760

SOURCE : Cellebrite Inc.

TEMENOS CHOSEN BY CEBUANA LHUILLIER BANK TO SCALE THE PHILIPPINES' RURAL BANKING SERVICES

KUALA LUMPUR, Aug 17 (Bernama) -- Temenos announced Cebuana Lhuillier Bank has selected the company to modernise its core banking platform, helping the bank, which serves seven million Filipinos, to quickly launch new banking products and scale efficiently.

According to a statement, with Temenos, Cebuana Lhuillier Bank aims to expand its product offerings and grow to more than 11 million customers over five years.

Temenos Managing Director – APAC, Ramki Ramakrishnan said: “We are delighted to welcome Cebuana Lhuillier Bank as the newest member of our Temenos family in the Philippines.

“With a robust presence in the country, our partnership with Cebuana Lhuillier Bank reinforces Temenos' position as a compelling choice for banks across various sizes and segments, including rural and thrift banks.”

Cebuana Lhuillier Bank provides credit and savings accounts to individuals, micro, small and medium enterprises to grow their personal or business finances.

With more than half of the Philippines’ 113 million population living in rural areas, banks such as Cebuana Lhuillier Bank play a crucial role in serving the financial needs of those residing in remote and underserved areas of the country.

Temenos’ core banking platform gives Cebuana Lhuillier Bank flexibility and agility to manage customer accounts and transactions with greatly improved performance and efficiency, and offer personalised products, faster and at lower cost.

It means Cebuana Lhuillier Bank can introduce affordable new lending products, such as motorcycle loans, to attract new customers while also growing sustainably, and the solution will be implemented by Temenos’ delivery partner, Orion Innovation.

As a regulated financial institution, supervised by Bangko Sentral ng Pilipinas, the Temenos solution also assists the bank to adapt more easily to changing market conditions and local regulatory requirements.

While Cebuana Lhuillier Bank will initially deploy the Temenos solution in its on-premise datacentre, the cloud-native solution gives the bank the flexibility to easily migrate to the cloud in future.

-- BERNAMA

HEURON TO SHOWCASE SOLUTIONS AT SINGAPORE NEURORADIOLOGY CONGRESS

Heuron, a medical AI solution company, participates in the Asian-Oceanian Congress of Neuroradiology 2023 (AOCNR 2023), which is held in Singapore from August 18th. Heuron showcases its neurodegenerative disease AI solution such as Heuron AgingCare Suite, and its integrated stroke solution, Heuron StroCare Suite, to engage in global collaborations and partnerships. (Graphic: Business Wire)

KUALA LUMPUR, Aug 17 (Bernama) -- Heuron, a medical artificial intelligence (AI) solution company, announced its participation in the Asian-Oceanian Congress of Neuroradiology 2023 (AOCNR 2023) which will be held in Singapore from Aug 18-20.

An international academic conference organised by the Asian Oceanian Society of Neuroradiology, AOCNR gathers over a thousand medical professionals from Asia, Oceania, North America, Europe and the rest of the world.

Heuron Chief Executive Officer, Donghoon Shin said the company was seeing significant interests in its products from Asian countries, and actively expanding its business presence.

“At the AOCNR 2023, we aim to strongly enhance competitiveness of our products, and seek partnerships with various institutions and medical professionals through research collaborations, demo presentations, and more,” he said in a statement.

During this event, Heuron will showcase its neurodegenerative disease AI solution such as Heuron AgingCare Suite, and its integrated stroke solution, Heuron StroCare Suite, to engage in global collaborations and partnerships.

Heuron AgingCare Suite includes neurodegenerative diseases solutions for Parkinson's disease (Heuron IPD and Heuron NI), and Alzheimer's disease (Heuron AD and Heuron Brain PET).

Meanwhile, Heuron StroCare Suite is an integrated AI solution that enables one-stop classification of patients with cerebral hemorrhage and cerebral infarction with non-contrast computed tomography (CT).

Heuron offers diagnostic AI software that automatically quantitatively analyses neurodegenerative brain disorders' medical images including Parkinson's disease, dementia, and strokes to aid accurate and swift decision-making by medical professionals.

-- BERNAMA

TDCX INC. TO REPORT SECOND QUARTER 2023 RESULTS

SINGAPORE, Aug 11 (Bernama-BUSINESS WIRE) -- TDCX Inc. (“TDCX” or the “Company”) (NYSE: TDCX), an award-winning digital customer experience solutions provider for innovative technology and other blue-chip companies, plans to announce its second quarter unaudited financial results on August 23, 2023, U.S. Eastern Time, after the U.S. market closes.

On that day, the TDCX senior management will host a conference call to discuss the unaudited financial results.

A live webcast of this conference call will be available on the TDCX website. Access information on the conference call and webcast is as follows:
 

Date and time:		August 23, 2023, 8:30 PM (U.S. Eastern Time) August 24, 2023, 8:30 AM (Singapore / Hong Kong Time)
Webcast link:		https://events.q4inc.com/earnings/TDCX/Q2-2023
Dial in numbers:		U.S. Toll Free: +1 833 470 1428	U.S. (Local): +1 404 975 4839
		Singapore: +65 3158 0255	Hong Kong: +852 5803 6418
		UK Toll Free: +44 808 189 6484	All others: Dial In numbers
Participant Access Code:465393

A replay of the conference call will be available at TDCX’s investor relations website (investors.tdcx.com). An archived webcast will be available at the same link above.

About TDCX Inc.

Singapore-headquartered TDCX provides transformative digital CX solutions, enabling world-leading and disruptive brands to acquire new customers, to build customer loyalty and to protect their online communities.

TDCX helps clients achieve their customer experience aspirations by harnessing technology, human intelligence and its global footprint. It serves clients in fintech, gaming, technology, travel and hospitality, digital advertising and social media, streaming and e-commerce. TDCX’s expertise and strong footprint in Asia has made it a trusted partner for clients, particularly high-growth, new economy companies, looking to tap the region’s growth potential.

TDCX’s commitment to delivering positive outcomes for our clients extends to its role as a responsible corporate citizen. Its Corporate Social Responsibility program focuses on positively transforming the lives of its people, its communities and the environment.

TDCX employs more than 18,400 employees across 30 campuses globally, specifically in Brazil, Colombia, Hong Kong, India, Japan, Malaysia, Mainland China, Philippines, Romania, Singapore, South Korea, Spain, Thailand, Türkiye, and Vietnam. For more information, please visit www.tdcx.com.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20230810994022/en/

Contact

For enquiries:
Investors / Analysts: Jason Lim, lim.jason@tdcx.com
Media: Eunice Seow, eunice.seow@tdcx.com

Source : TDCX INC.

Cloudflare New Impact Initiative To Protect Vulnerable School Districts

KUALA LUMPUR, Aug 9 (Bernama) -- Cloudflare Inc, the security, performance and reliability company helping to build a better Internet, has introduced Project Cybersafe Schools, a new initiative aimed at improving cybersecurity for K-12 public school districts.

In a statement, Cloudflare said this new programme will provide a suite of Zero Trust cybersecurity solutions to give small school districts faster, safer Internet browsing and email security, at no cost, and with no time limit.

On Aug 7, the White House hosted its Back to School Safely: Cybersecurity for K-12 Schools event. With Project Cybersafe Schools, Cloudflare shared their commitment with the White House to help under-resourced and vulnerable schools better secure themselves.

“Every day, our schools face cyberattacks that can slow Internet access, threaten leaks of confidential student data, and hinder their ability to teach children in a secure online space.

“As another school year is set to begin, we are committed, in tandem with the White House, to help our nation’s schools better protect themselves so they can focus on what they do best: teaching students,” said Cloudflare co-founder and Chief Executive Officer, Matthew Prince.

Unlike many colleges, universities and larger school districts, smaller school districts often lack the capacity or funding to protect against cyber threats, making schools a prime target for cybercriminals.

Eligible school districts will have access to Zero Trust cybersecurity services to help them safeguard inboxes from targeted cyberattacks; stop the leak of confidential student data; and improve overall Internet browsing experience.

-- BERNAMA

NORTH RIDGE PARTNERS, GP BULLHOUND TIE UP EXCLUSIVE COLLABORATION

KUALA LUMPUR, Aug 9 (Bernama) -- North Ridge Partners (NRP) and GP Bullhound have announced an exclusive collaboration which will see NRP support GP Bullhound’s clients across Asia Pacific (APAC) while GP Bullhound support NRP’s clients across Europe, the United Kingdom (UK) and North America.

The partnership represents a formalisation of the firms’ multi-year relationship, adding to their mutual strength and depth in global coverage of technology investors and strategic consolidators.

In a statement, NRP said this will help unlock growth in key geographies, supporting founders and investors to access a thriving interconnected technology ecosystem.

“We are delighted to formalise our relationship with GP Bullhound. With our longstanding relationship with GP Bullhound, we are excited about the cultural alignment and special relationship we are developing.

“Together, we offer an extensive network in Southeast Asia, Australia and New Zealand, providing a comprehensive global toolkit for investors, founders and tech company boards,” said NRP Co-founder and Chair, Roger Sharp.

Meanwhile, GP Bullhound Co-founder and Managing Partner, Hugh Campbell said: “Our partnership with NRP represents a milestone in our mission to support exceptional technology companies as they scale worldwide.

“We are excited to collaborate with a like-minded and highly successful partner to accelerate our strong track records in these regions and provide the highest quality investment and advisory services to tech companies.”

Together, GP Bullhound and NRP have completed over 700 transactions serving both private and public tech companies in geographic destinations as diverse as Indonesia, Vietnam, Thailand, Singapore, Australia, China and New Zealand, with cross border transactions involving European, UK, APAC, and American acquirers and investors.

-- BERNAMA

CELLEBRITE WINS FIVE FORENSIC FOCUS 4:CAST AWARDS, REINFORCING STANDING AS DIGITAL INTELLIGENCE LEADER

Cellebrite wins across multiple categories, including DFIR Commercial Tool and DFIR Team of the Year

TYSONS CORNER, Va. and PETAH TIKVA, Israel and AUSTIN, Texas, Aug 8 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, is thrilled to win five prestigious 2023 Forensic Focus 4:cast Awards.

“Cellebrite’s nominations and awards highlight our leadership and commitment to continually innovate, delivering the most effective and advanced Digital Intelligence and investigative solutions to market,” says Leeor Ben-Peretz, Cellebrite Chief Strategy Officer. “This consistent recognition validates that Cellebrite’s Digital Intelligence platform is the dominant solution, fueled by the best leadership and R&D teams.”

Cellebrite is honored and excited to receive the following awards, emphasizing our industry prominence, product superiority and unsurpassed community engagement:

DFIR Commercial Tool of the Year: Received in recognition of the reliability and innovation of Cellebrite’s complete, end-to-end solution suite where every tool we produce speeds up and helps validate data pertaining to investigations.

DFIR Team of the Year: With acknowledgement Cellebrite as not only a vendor to the DFIR community but truly part of their team, working together side by side to promote the concept of “trust but verify”.

DFIR Blog of the Year: Received for 'Ask the Expert', a platform utilized to share our findings and insights with the community.

DFIR CTF (Capture the Flag) of the Year: Following its introduction in 2020, Cellebrite rapidly established its CTF event as industry standard for in-depth CTFs.

DFIR Social Media Influencer of the Year: Honoring Cellebrite’s Heather Mahalik—a consistent voice to the community through regular content, tips, tricks, and hints for the DFIR community. She also hosts frequent Cellebrite webinars and podcasts, including Tip Tuesdays, Fundamentals Matter, I Beg to DFIR, and our latest 'Dig For' YouTube series.

About Cellebrite

Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.

Media
Victor Cooper
Sr. Director of Corporate Communications + Content Operations
Victor.cooper@cellebrite.com
+1 404.804.5910

Investor Relations
Andrew Kramer
Vice President, Investor Relations
investors@cellebrite.com
+1 973.206.7760

Source: Cellebrite Inc.

Greener Future: Forest City Pledges To Sustainable Building Practices

KUALA LUMPUR, Aug 4 (Bernama) -- Country Garden’s Forest City in Johor is a vast new coastal development that has pledged to implement sustainable building practices throughout the entire project.

Embracing environmental management principles, Forest City has set a new benchmark in urban planning and infrastructure to protect the surrounding ecosystems while creating a thriving, modern metropolis.

In Forest City, considerations for sustainable development are being integrated into every aspect of new urban design and infrastructure planning, according to a statement.

The buildings incorporate energy-saving features such as water recycling systems, renewable energy sources and advanced water conservation systems, ensuring responsible water usage and minimising waste.

Its eco-friendly water recycling system gathers household sewage and wastewater via a sewage pipeline system for processing, while gathered rainwater undergoes filtration and storage, later reused in the rainwater pump rooms across each plot to water the vertical greenery.

Furthermore, any surplus rainwater is systematically collected and stored in the water recycling system for irrigating green plants during the dry seasons.

Balancing urban development with nature conservation lies at the core of Forest City's mission, in which the project has diligently preserved the surrounding mangroves and natural habitats via meticulous planning, to ensure the harmonious coexistence of the city and environment.

With its "Water Cycle System and Sponge City Concept Application" project, Forest City has won the Asian Townscape Jury's Award and as the project progresses, it remains committed to green practices and environmental protection.

-- BERNAMA

ZENAS BIOPHARMA ANNOUNCES PUBLICATION OF PHASE 2 STUDY OF OBEXELIMAB, AN INVESTIGATIONAL TREATMENT FOR IGG4-RELATED DISEASE (IGG4-RD), IN THE LANCET RHEUMATOLOGY

Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active IgG4-RD

Results support the continued development of obexelimab for the treatment of IgG4-RD and potentially other B cell-mediated autoimmune conditions

WALTHAM, Mass., Aug 2 (Bernama-GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, announces The Lancet Rheumatology has published findings from a Phase 2 study evaluating obexelimab for the treatment of patients with IgG4-Related Disease (IgG4-RD). Based on the results of this study, a Phase 3 study in patients with IgG4-RD is ongoing to further investigate the efficacy and safety of obexelimab administered as a subcutaneous injection.

IgG4-RD is a chronic, immune-mediated fibro-inflammatory disease that can affect multiple organs including the major salivary glands, orbits, lacrimal glands, pancreas, biliary tree, lungs, kidneys, and retroperitoneum. Approximately 20,000 patients are diagnosed with IgG4-RD in the United States alone. Despite its increasing recognition, there remains a need for further research and effective therapeutic options for individuals living with this debilitating disease.

Across the world, the use of glucocorticoids is widely considered to be the standard of care for treating IgG4-RD. There are no approved treatment options for this condition. While commonly used, glucocorticoids and available B cell depleting therapies rarely lead to long-term, treatment-free remissions, and are associated with a high risk of toxicity in these patients. Such therapies also impair vaccine responses, including those for SARS-CoV-2 and influenza.

In a prospective, open-label, single arm, single-center pilot study to assess the efficacy and safety of obexelimab in the treatment of patients with IgG4-RD (clinicaltrials.gov registration NCT02725476), obexelimab demonstrated strong improvement in the IgG4-RD Responder Index, a measure of disease activity, by inhibiting B cell function, without depleting B cells.

The published manuscript, titled “Obexelimab for the Treatment of Patients with IgG4-Related Disease: An Open-Label, Single-Arm, Pilot Study to Evaluate Efficacy, Safety, and Mechanism of Action,” is available online and will appear in the August issue of The Lancet Rheumatology 2023;5(8) [E428-E429].

The following are the key findings in the paper:

• Obexelimab produced rapid, strong, and sustained clinical improvement, including complete remission (IgG4-RD Responder Index score of 0), in most patients with active IgG4-RD.
• During obexelimab treatment, reductions in circulating B cells, including plasmablasts, were observed without evidence of cell death.
• Additionally, reduction of circulating B cells and rapid return to near normal levels after treatment discontinuation suggests that obexelimab may lead to B cell sequestration in lymphoid organs or the bone marrow.
• Obexelimab was well tolerated. The majority of treatment-related adverse events were grades 1 or 2, with the most common adverse events being gastrointestinal infusion-related events, most of which were mild.

“Our findings are a significant step forward in understanding the underlying mechanisms of IgG4-Related Disease; paving the way for more targeted treatment strategies,” said John Stone, MD, MPH, Professor of Medicine at Harvard Medical School, and the Edward A. Fox Chair in Medicine at Mass General Hospital. “Our team is honored to have our research recognized by The Lancet Rheumatology, and we are immensely grateful to the patients who participated in this groundbreaking study.”

About Obexelimab

Obexelimab is an investigational Phase 3-stage, bifunctional, non-cytolytic, humanized monoclonal antibody that mimics the action of antigen-antibody complexes by binding CD19 and FcγRIIb to inhibit B-lineage cell activity. In several early-stage clinical studies in various autoimmune diseases, 198 subjects were treated with obexelimab. In these clinical studies, obexelimab demonstrated effective inhibition of B cell function without depleting the cells, resulting in encouraging treatment effect in patients with various autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc.

More information on the Phase 3 (INDIGO) study for the treatment of IgG4 Related Disease is available at clinicaltrials.gov: NCT05662241.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients around the world. With clinical development and operations globally, Zenas is advancing a deep and balanced global portfolio of potential first- and best-in-class autoimmune therapeutics in areas of high unmet medical need while meeting the value requirements of the dynamic global healthcare environment. The company’s pipeline continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn. 

http://mrem.bernama.com/viewsm.php?idm=46711